Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, Yu K, Niu W, Coppola G, Coughlin SE, Lee SE, Dries DR, Almeida S, Geschwind DH, Gao FB, Miller BL, Farese RV, Posner BA, Yu G, Herz J. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011 May 6;286(18):16101-8. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. The primary outcome data from the reaZin study appear to be consistent with the proposed action of the intervention. The three cognitive and functional measures used for the series of secondary outcomes are appropriate, but the small size of the sample means that the study was underpowered with respect to any clinical outcome measures. The small sample size was probably responsible also for the lack of balance in baseline measures across the randomized groups. Whether one should see the preliminary clinical outcome results as encouraging is a matter of judgment. The poster presentation does not make it clear whether the composite outcome was specified a priori. If not, the meaning of the p-value of 0.15 is hard to discern. In any event, I cannot agree with the authors' conclusion that these results provide a "strong trend toward cognitive benefit favoring the treatment group."

    View all comments by John Breitner

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Feeding Frenzy—Therapeutics Tap Tryptophan, Cathepsins, HDACs, Zinc
  2. Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma?
  3. Case Studies Crystallize Trial Ideas at FTD Conference
  4. Microglial Progranulin Douses Neural Inflammation
  5. Progranulin-Boosting Drug Moves into Phase 2 for Frontotemporal Dementia

Therapeutics

  1. FRM-0334